EPO: In-house welcome opposition speed but want clearer BoA data
Oppositions are speeding up but in-house lawyers say data on how successful appeals are at a higher level would have more practical significance
In-house lawyers in the pharmaceutical industry say data showing that EPO opposition procedures are speeding up provides clarity but that more information should be published on how successful subsequent appeals are.
Counsel at pharma companies across Europe say more data...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.